GSK1070916Aurora B/C inhibitor CAS# 942918-07-2 |
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- Necrostatin-1
Catalog No.:BCC2247
CAS No.:4311-88-0
- IOX2(Glycine)
Catalog No.:BCC2229
CAS No.:931398-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 942918-07-2 | SDF | Download SDF |
PubChem ID | 46885626 | Appearance | Powder |
Formula | C30H33N7O | M.Wt | 507.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GSK-1070916A | ||
Solubility | DMSO : 10 mg/mL (19.70 mM; Need ultrasonic) | ||
Chemical Name | 3-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea | ||
SMILES | CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC(=CC=C5)CN(C)C | ||
Standard InChIKey | QTBWCSQGBMPECM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B and C with IC50 value of 3.5 nM and 6.5 nM, respectively. | |||||
Targets | Aurora B | Aurora C | ||||
IC50 | 3.5 nM | 6.5 nM |
GSK1070916 Dilution Calculator
GSK1070916 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9699 mL | 9.8497 mL | 19.6994 mL | 39.3988 mL | 49.2485 mL |
5 mM | 0.394 mL | 1.9699 mL | 3.9399 mL | 7.8798 mL | 9.8497 mL |
10 mM | 0.197 mL | 0.985 mL | 1.9699 mL | 3.9399 mL | 4.9248 mL |
50 mM | 0.0394 mL | 0.197 mL | 0.394 mL | 0.788 mL | 0.985 mL |
100 mM | 0.0197 mL | 0.0985 mL | 0.197 mL | 0.394 mL | 0.4925 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1].
GSK1070916 is a reversible ATP-competitive inhibitor of Aurora B and Aurora C with Ki values of 0.38nM and 1.5nM, respectively. The SPA assay shows GSK1070916 has a good selectivity over Aurora A. It inhibits Aurora B with IC50 value of 5nM but 1259nM for Aurora A. It is also reported that treatment of GSK1070916 suppresses cell proliferation in A549 human lung cancer cells with EC50 value of 7nM. Moreover, both in vitro and in vivo assays demonstrate GSK1070916 can inhibit the phosphorylation of histone H3, which is a substrate of Aurora B. GSK1070916 can also suppress tumor growth in mice with HL-60 tumor xenografts [1].
References:
[1] Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
- Acetyldihydromicromelin A
Catalog No.:BCN4492
CAS No.:94285-22-0
- Dihydromicromelin B
Catalog No.:BCN4491
CAS No.:94285-06-0
- 5-Hydroxy-7,8,2',5'-tetramethoxyflavone 5-O-glucoside
Catalog No.:BCN1302
CAS No.:942626-75-7
- 1,5,15-Tri-O-methylmorindol
Catalog No.:BCN4490
CAS No.:942609-65-6
- Walsuronoid B
Catalog No.:BCN4489
CAS No.:942582-15-2
- PF-03814735
Catalog No.:BCC2184
CAS No.:942487-16-3
- Nemoralisin
Catalog No.:BCN4488
CAS No.:942480-13-9
- VKGILS-NH2
Catalog No.:BCC3953
CAS No.:942413-05-0
- Cycloart-24-ene-1alpha,2alpha,3beta-triol
Catalog No.:BCN7983
CAS No.:942407-97-8
- Scutebarbatine I
Catalog No.:BCN1026
CAS No.:960302-84-5
- 20-Dehydroeupatoriopicrin semiacetal
Catalog No.:BCN7370
CAS No.:94234-24-9
- PI 828
Catalog No.:BCC7494
CAS No.:942289-87-4
- CCT129202
Catalog No.:BCC2187
CAS No.:942947-93-5
- 12-Hydroxyganoderic acid D
Catalog No.:BCN8051
CAS No.:942950-96-1
- 3beta-(2-O-alpha-L-Rhamnopyranosyl-beta-D-xylopyranosyloxy)-23-hydroxyoleana-12-ene-28-oic acid 6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl ester
Catalog No.:BCC8948
CAS No.:942997-00-4
- DGAT-1 inhibitor 2
Catalog No.:BCC1530
CAS No.:942999-61-3
- H-Phe(4-NH2)-OH
Catalog No.:BCC3152
CAS No.:943-80-6
- GAP-134 Hydrochloride
Catalog No.:BCC1589
CAS No.:943133-81-1
- GAP-134
Catalog No.:BCC1588
CAS No.:943134-39-2
- Chlorahololide D
Catalog No.:BCN4493
CAS No.:943136-39-8
- Peroxydehydrotumulosic acid
Catalog No.:BCN3739
CAS No.:943225-53-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Ethyl p-nitrobenzyl carbonate
Catalog No.:BCN3285
CAS No.:943409-69-6
- Sappanchalcone
Catalog No.:BCN4494
CAS No.:94344-54-4
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.[Pubmed:20335034]
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
Novel Aurora inhibitors were identified truncating clinical candidate GSK1070916. Many of these truncated compounds retained potent activity against Aurora B with good antiproliferative activity. Mechanistic studies suggested that these compounds, depending on the substitution pattern, may or may not exert their antiproliferative effects via inhibition of Aurora B. The SAR results from this investigation will be presented with an emphasis on the impact structural changes have on the cellular phenotype.
High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916.[Pubmed:21762492]
J Transl Med. 2011 Jul 15;9:110.
BACKGROUND: Aurora kinases play critical roles in mitosis and are being evaluated as therapeutic targets in cancer. GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and C. Translation of predictive biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies, especially novel inhibitors such as GSK1070916. METHODS: 59 Hematological cancer-derived cell lines were used as models for response where in vitro sensitivity to GSK1070916 was based on both time and degree of cell death. The response data was analyzed along with karyotype, transcriptomics and somatic mutation profiles to determine predictors of response. RESULTS: 20 cell lines were sensitive and 39 were resistant to treatment with GSK1070916. High chromosome number was more prevalent in resistant cell lines (p-value = 0.0098, Fisher Exact Test). Greater resistance was also found in cell lines harboring polyploid subpopulations (p-value = 0.00014, Unpaired t-test). A review of NOTCH1 mutations in T-ALL cell lines showed an association between NOTCH1 mutation status and chromosome number (p-value = 0.0066, Fisher Exact Test). CONCLUSIONS: High chromosome number associated with resistance to the inhibition of Aurora B and C suggests cells with a mechanism to bypass the high ploidy checkpoint are resistant to GSK1070916. High chromosome number, a hallmark trait of many late stage hematological malignancies, varies in prevalence among hematological malignancy subtypes. The high frequency and relative ease of measurement make high chromosome number a viable negative predictive marker for GSK1070916.
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.[Pubmed:20420387]
J Med Chem. 2010 May 27;53(10):3973-4001.
The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with K(i)* values of 0.38 +/- 0.29 and 1.5 +/- 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC(50) = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.
3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase.[Pubmed:21151441]
Int J Mol Sci. 2010 Nov 2;11(11):4326-47.
Development of anticancer drugs targeting Aurora B, an important member of the serine/threonine kinases family, has been extensively focused on in recent years. In this work, by applying an integrated computational method, including comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), homology modeling and molecular docking, we investigated the structural determinants of Aurora B inhibitors based on three different series of derivatives of 108 molecules. The resultant optimum 3D-QSAR models exhibited (q(2) = 0.605, r(2) (pred) = 0.826), (q(2) = 0.52, r(2) (pred) = 0.798) and (q(2) = 0.582, r(2) (pred) = 0.971) for MK-0457, GSK1070916 and SNS-314 classes, respectively, and the 3D contour maps generated from these models were analyzed individually. The contour map analysis for the MK-0457 model revealed the relative importance of steric and electrostatic effects for Aurora B inhibition, whereas, the electronegative groups with hydrogen bond donating capacity showed a great impact on the inhibitory activity for the derivatives of GSK1070916. Additionally, the predictive model of the SNS-314 class revealed the great importance of hydrophobic favorable contour, since hydrophobic favorable substituents added to this region bind to a deep and narrow hydrophobic pocket composed of residues that are hydrophobic in nature and thus enhanced the inhibitory activity. Moreover, based on the docking study, a further comparison of the binding modes was accomplished to identify a set of critical residues that play a key role in stabilizing the drug-target interactions. Overall, the high level of consistency between the 3D contour maps and the topographical features of binding sites led to our identification of several key structural requirements for more potency inhibitors. Taken together, the results will serve as a basis for future drug development of inhibitors against Aurora B kinase for various tumors.